CTLA4 and cancer: Recently, cancer immunotherapy has been highlighted and clinically validated for many cancers which enhances tumor-killing T cell functions including immune checkpoint blockade such as anti-PD-1 and anti-CTLA-4 antibodies, engineered T cell therapy utilizing chimeric antigen receptors (CAR), and cancer vaccines, etc46–50.